Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

9.1%

4 terminated out of 44 trials

Success Rate

86.2%

-0.3% vs benchmark

Late-Stage Pipeline

18%

8 trials in Phase 3/4

Results Transparency

28%

7 of 25 completed with results

Key Signals

7 with results86% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (10)
Early P 1 (1)
P 1 (4)
P 2 (8)
P 3 (8)

Trial Status

Completed25
Unknown10
Withdrawn5
Terminated4

Trial Success Rate

86.2%

Benchmark: 86.5%

Based on 25 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT04306393Phase 2CompletedPrimary

Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19

NCT04584658Completed

Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)

NCT04558476Phase 2Completed

Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation

NCT05097677Completed

Follow-up of Covid-19 Long Term Sequelae

NCT04517630Completed

Renal Biomarkers in AKI and COVID-19

NCT04476979Phase 2Completed

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

NCT04664075Terminated

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

NCT04382391Not ApplicableTerminated

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04629703Phase 3Completed

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04325646CompletedPrimary

Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France

NCT04644159CompletedPrimary

Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]

NCT04853199Early Phase 1CompletedPrimary

Quercetin In The Treatment Of SARS-COV 2

NCT04456426Withdrawn

Characteristics of Patients With COVID-19 in Meta State, Colombia

NCT04657406Unknown

Expanded Access to Zofin for Patients With COVID-19

NCT04366908Phase 2Completed

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

NCT04290871Phase 2Withdrawn

Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.

NCT04327505Phase 2TerminatedPrimary

Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19

NCT04822818Phase 3Completed

EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19

NCT04443673Not ApplicableTerminated

Glycine Supplement for Severe COVID-19

NCT04838795Phase 3CompletedPrimary

Sisonke (Together): OPEN LABEL TRIAL COVID-19

Scroll to load more

Research Network

Activity Timeline